Abstract
Two boys with idiopathic growth hormone (GH) deficiency developed hemolysis at 2 months and 4 months, respectively, after the start of GH replacement therapy. The hemolysis was subclinical and was noticed on routine laboratory tests. Although there was no direct evidence for a causal relationship between the incident and GH therapy, no other couse was found in these 2 patients. There were no family histories suggesting hemolysis, although we did not perform tests among the family members of either patient. Despite the continuation of GH administration, the hemolysis was transient and no other adverse effects were observed during the subsequent 4 years. Such hemolytic episodes could easily be overlooked even on routine laboratory tests during GH treatment.
